Hyperphosphatemia and phosphate binders: effectiveness and safety

Area of Science:

• Nephrology
• Cardiology
• Biochemistry

Background:

• Hyperphosphatemia is a common complication in chronic kidney disease (CKD), escalating with renal failure progression.
• Elevated phosphate levels are linked to increased FGF-23, secondary hyperparathyroidism, and vascular calcification, contributing to cardiovascular events and mortality in CKD patients.
• Phosphate itself is implicated as a risk factor for CKD progression, underscoring the importance of maintaining target serum phosphorus levels for improved life expectancy.

Discussion:

• Current strategies for hyperphosphatemia management include dietary phosphate restriction, dialysis, and phosphate binders.
• Calcium-based phosphate binders may cause adverse effects like hypercalcemia and vascular calcification.
• Sevelamer hydrochloride and lanthanum carbonate present effective and safer alternatives for managing hyperphosphatemia.

Key Insights:

• Controlling serum phosphorus is crucial for CKD patient survival and mitigating cardiovascular complications.
• Phosphate binders play a vital role in managing hyperphosphatemia, but their selection requires careful consideration.
• Individualized treatment approaches are necessary, balancing efficacy, safety, and healthcare costs.

Outlook:

• Further research into novel phosphate-lowering strategies is warranted.
• Long-term comparative studies on the safety and efficacy of different phosphate binders are needed.
• Integrating phosphate management into comprehensive CKD care pathways can improve patient prognosis.